Detalles de la búsqueda
1.
Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study.
Rheumatology (Oxford)
; 62(5): 1851-1859, 2023 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36130275
2.
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.
Ann Rheum Dis
; 80(8): 1014-1021, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33827787
3.
Response to: 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang.
Ann Rheum Dis
; 82(7): e169, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34172504
4.
Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
J Dermatol
; 48(6): 807-817, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33373480
Resultados
1 -
4
de 4
1
Próxima >
>>